Immunomodulatory drugs in AL amyloidosis

Critical Reviews in Oncology/hematology
T JelinekRoman Hajek

Abstract

Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients. Immunomodulatory drugs (IMiDs) are currently used in newly diagnosed patients as well as in salvage therapy in relapsed/refractory patients. IMiDs have a pleiotropic effect on malignant cells and the exact mechanism of their action has been described recently. Thalidomide is the most ancient representative, effective but toxic. Lenalidomide seems to be more effective, nevertheless the toxicity remains high, especially in patients with renal insufficiency. Pomalidomide is the newest IMiD used in this indication with a good balance between efficacy and tolerable toxicity and represents the most promising compound. This review is focused on the evaluation of all three representatives of IMiDs and their roles in the treatment of this malignant disorder.

References

Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·R M HinsonE Shacter
Dec 24, 1997·Leukemia & Lymphoma·M V DhodapkarB Barlogie
Feb 28, 2004·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Angela DispenzieriMorie A Gertz
Apr 2, 2004·Nature Reviews. Cancer·J Blake BartlettAngus G Dalgleish
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela DispenzieriAllan S Jaffe
Nov 21, 2007·Haematologica·Efstathios KastritisMeletios A Dimopoulos
Jun 27, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Merlini, G Palladini
Jul 25, 2009·Clinical Reviews in Allergy & Immunology·Anupama BhatM Eric Gershwin
Aug 14, 2009·Journal of Hematology & Oncology·Venumadhav KotlaAmit Verma
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarMorie A Gertz
Jun 26, 2012·Leukemia Research·Lenka SedlarikovaRoman Hajek
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni PalladiniGiampaolo Merlini
Jan 9, 2013·British Journal of Haematology·Moshe E Gatt, Giovanni Palladini

❮ Previous
Next ❯

Citations

Oct 22, 2016·Current Problems in Cancer·Jason Kidd, Daniel E Carl
Aug 11, 2018·British Journal of Haematology·Faye A SharpleyAshutosh Wechalekar
Oct 21, 2017·Blood Cancer Journal·T JelinekR Hajek
Dec 7, 2018·Frontiers in Immunology·Tomas JelinekRoman Hajek
Apr 15, 2017·Blood·Donna E Reece
Oct 22, 2020·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Xianghua HuangZhihong Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Expert Review of Hematology
Swati Andhavarapu, Vivek Roy
Current Hematologic Malignancy Reports
Martha Q Lacy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Martha Q LacyS Vincent Rajkumar
© 2021 Meta ULC. All rights reserved